Comparison of IPX066 with carbidopa–levodopa plus entacapone in advanced PD patients  by Stocchi, Fabrizio et al.
lable at ScienceDirect
Parkinsonism and Related Disorders 20 (2014) 1335e1340Contents lists avaiParkinsonism and Related Disorders
journal homepage: www.elsevier .com/locate/parkreldisComparison of IPX066 with carbidopaelevodopa plus entacapone
in advanced PD patients
Fabrizio Stocchi a, *, Ann Hsu b, Sarita Khanna b, Aaron Ellenbogen c, Andreas Mahler d,
Grace Liang e, Ulrich Dillmann f, Robert Rubens b, Sherron Kell b, Suneel Gupta b
a Institute for Research and Medical Care (IRCCS) San Raffaele, Rome, Italy
b Impax Laboratories, Hayward, CA, USA
c Quest Research Institute, Farmington Hills, MI, USA
d Neurozentrum Achim, Niedersachsen, Germany
e The Parkinson's Institute and Clinical Center, Sunnyvale, CA, USA
f Saarland University, Homburg/Saar, Germanya r t i c l e i n f o
Article history:
Received 27 March 2014
Received in revised form
30 June 2014
Accepted 3 August 2014
Keywords:
IPX066
Levodopa
Entacapone
Parkinson's disease
“Off” time
Motor ﬂuctuations* Corresponding author. Dept. of Neurology, IRCCS
235, 00163 Rome, Italy. Tel.: þ39 0652252311; fax: þ
E-mail addresses: fabrizio.stocchi@fastwebnet.it, f
fabrizio.stocchi@tin.it (F. Stocchi).
http://dx.doi.org/10.1016/j.parkreldis.2014.08.004
1353-8020/© 2014 The Authors. Published by Elseviera b s t r a c t
Background: IPX066, an investigational extended-release carbidopaelevodopa (CD-LD) preparation, has
demonstrated a rapid attainment and prolonged maintenance of therapeutic LD plasma concentrations
in advanced Parkinson's disease (PD). This phase-3 crossover study assessed its efﬁcacy and safety vs. CD-
LD plus entacapone (CL þ E).
Methods: At baseline, all patients had motor ﬂuctuations despite a stable regimen of CL þ E or CD-LD-
entacapone combination tablets (CLE). The study included a 6-week conversion from CL þ E or CLE to
IPX066, followed by two 2-week, double-blind crossover treatment periods in randomized order, one on
IPX066 (and placebo CL þ E), the other on CL þ E (and placebo IPX066), separated by 1-week open-label
IPX066 treatment. The primary efﬁcacy measure was mean percent daily “off” time during waking hours
(from patient diaries).
Results: Of 91 randomized patients, 84 completed the study. Their median daily LD dosage was 1495 mg
from IPX066 and 600 mg from CL þ E, corresponding, after correction for bioavailability, to an
approximately 22% higher LD exposure on IPX066. Compared with CL þ E, IPX066 demonstrated a lower
percent “off” time (24.0% vs. 32.5%; p < 0.0001), lower “off” time (3.8 vs. 5.2 h/day; p < 0.0001), and
higher “on” time without troublesome dyskinesia (11.4 vs. 10.0 h/day; p < 0.0001). Other endpoints,
including patient-reported treatment preference, also favored IPX066 (p < 0.05). During double-blind
treatment, 20.2% and 13.6% of patients reported adverse events on IPX066 and CL þ E, respectively.
The most common were dyskinesia (4 patients), insomnia (3), and confusional state (3) for IPX066, and
fall (2) for CL þ E.
Conclusions: In advanced PD, IPX066 showed improved efﬁcacy, compared with CL þ E, and appeared to
be well tolerated.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
In Parkinson's disease (PD), no medical or surgical therapy has
been shown to provide anti-parkinsonian beneﬁts superior to those
of levodopa (LD) [1]. However, as PD progresses, chronic LD treat-
ment is associated with the development of motor complications,San Raffaele, Via della Pisana
39 0652255502.
abrizio.stocchi@sanraffaele.it,
Ltd. This is an open access article uincluding motor ﬂuctuations (such as wearing-off episodes,
reﬂecting a loss of beneﬁt between doses) and dyskinesia (which
may occur at therapeutic LD plasma concentrations). Although
motor ﬂuctuations are considered to be late complications of PD,
the ELLDOPA trial reported their emergence within 5e6 months
after initiation of immediate-release (IR) carbidopaelevodopa (CD-
LD) therapy [2,3]. In the extreme, patients may cycle between
disabling dyskinesias during “on” time and disabling parkinsonism
during “off” time.
Motor complications are thought to be caused by non-
physiologic ﬂuctuations in LD plasma concentrations [4], and are
the primary reason for surgical interventions in PD [5]. Accordingly,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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stable LD concentrations. Among them, entacapone acts as an in-
hibitor of catechol-O-methyl transferase (COMT), increasing LD
bioavailability, extending the LD elimination half-life, and pro-
longing LD effects [6e8]. Co-administration of entacaponewith CD-
LD (CL þ E) has been used to treat wearing-off [9e11]; however,
frequent dosing is still required, especially in patients with
advanced PD. For its part, the administration of entacapone in
carbidopaelevodopa-entacapone (CLE) combination tablets [12] to
patients with advanced PD has exhibited LD pharmacokinetics
similar to those of sustained-release CD-LD formulations [13].
Hence, there is a continuing need for alternative CD-LD treatment
options.
IPX066 (Impax Pharmaceuticals, a division of Impax Labo-
ratories, Inc., Hayward, CA, USA) is an investigational
extended-release (ER) formulation of CD-LD (1:4 ratio). In pa-
tients with advanced PD, it provided a rapid onset of clinical
effects, which lasted for approximately 6 h after a single dose
[14,15]. In the present study, it was compared with CL þ E in
advanced PD.Fig. 1. Study design (A) and2. Methods
This phase 3, randomized, double-blind, double-dummy, crossover study eval-
uated IPX066 and CL þ E in advanced PD patients who had been taking a stable
dosage of CL þ E or CLE. The study design (Fig. 1A) included a 6-week dose con-
version from CL þ E or CLE to IPX066, followed by two 2-week double-blind
crossover treatment periods (in randomized order), one on IPX066, the other on
CL þ E, separated by a 1-week open-label IPX066 treatment period. The study was
conducted in the US, Italy, Germany, and France, and was performed in accordance
with the Declaration of Helsinki. All sites received Institutional Review Board (IRB)
approval, and all patients provided written informed consent prior to participation
(CinicalTrials.gov: NCT01130493).
2.1. Study population
Study participants had advanced idiopathic PD [16] at Hoehn-Yahr stage IeIV,
diagnosed at age 30 years; 4 weeks of stable CL þ E or CLE treatment with a
dosing frequency 4 times/day and with a total LD IR dosage 400 mg/day; a 3-day
mean “off” time 2.5 h/day (per PD diary); and a Mini-Mental State Examination
score26. Concomitant use of dopamine agonists, monoamine oxidase-B inhibitors,
amantadine, or anticholinergics was permitted at stable dosage. Exclusion criteria
included atypical or secondary parkinsonism; non-responsiveness to LD; prior
neurosurgical PD treatment; active psychosis or current treatment with antipsy-
chotics; a history of peptic ulcer disease, upper gastrointestinal hemorrhage,
gastrointestinal surgery, narrow-angle glaucoma, malignant melanoma, orpatient disposition (B).
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hepatic impairment; or prior participation in an IPX066 study.2.2. Dosing
During 6-week dose conversion, each patient's initial dosage of open-label
IPX066 was based on the patient's daily LD dosage at study entry, using a dose-
conversion table provided in the study protocol. The initial dosing frequency was
3 times/day during waking hours. A bedtime dose was allowed if necessary. Dosing
>5 times/day was not allowed. After dose conversion, using a two-period crossover
design, patients were randomized to receive 2 weeks of double-blind IPX066 (and
placebo CL þ E) or double-blind CL þ E (and placebo IPX066) in double-dummy
fashion. IPX066 was administered as the individualized regimen achieved during
dose conversion and CL þ E as the patient's baseline regimen. Each patient then
crossed to 2 weeks of the alternative double-blind treatment. Because the dosing
frequency for IPX066 and CL þ E likely were different for many patients, these pa-
tients took IPX066 (or placebo) and CLE (or placebo) at different times throughout
the day. Between the two double-blind treatment periods, patients received 1 week
of open-label IPX066. No dose adjustments were permitted post-randomization,
and no CD-LD IR supplementation was allowed.2.3. Study medications
IPX066 capsules (Impax Pharmaceuticals, a division of Impax Laboratories Inc.,
Hayward CA) were supplied in four CD/LD strengths: 23.75/95, 36.25/145, 48.75/
195, and 61.25/245 mg. CL þ E was administered as CD-LD IR (Sinemet® 25/100 mg;
Merck & Co., Inc., Whitehouse Station NJ) plus entacapone (Comtan® 200 mg; Orion
Pharma, Espoo, Finland). Matching placebos for IPX066, CD-LD IR, and entacapone
were manufactured by Impax Laboratories. The placebo tablets for entacapone
contained a quantity of riboﬂavin sufﬁcient to mimic the potential urine discolor-
ation due to entacapone.Table 1
Demographic and clinical characteristics of the study population at baseline.
Variable All randomized
patients
Completer
patients2.4. Efﬁcacy endpoints
The primary efﬁcacy endpoint was mean percent “off” time during waking
hours, based on patient diaries during the last 3 days of each double-blind treat-
ment period. Key secondary efﬁcacy measures included “off” time, “on” time
without troublesome dyskinesia [17], Uniﬁed Parkinson's Disease Rating Scale
(UPDRS) Part II þ III scores (in the “on” state), and patient-reported preference for
treatment. A responder analysis evaluated the proportion of study completers
achieving improvement of at least 0.5, 1, 1.5, 2, and 3 h of reduction in “off” time
from baseline.
Health-related quality-of-life outcomes were evaluated using the EuroQol 5D
(EQ-5D) [18], the Medical Outcomes Study 36-item Short Form Survey (SF-36) [19],
and the Parkinson's Disease Sleep Scale (PDSS) [20].(N ¼ 91) (n ¼ 84)
Gender, n (%)
Male 68 (74.7) 64 (76.2)
Female 23 (25.3) 20 (23.8)
Age, years, mean ± SD 64.1 ± 9.3 64.0 ± 9.1
Race, n (%)
White 89 (97.8) 83 (98.8)
Other 2 (2.2) 1 (1.2)
Duration of PD, years, mean ± SD 10.0 ± 5.3 10.0 ± 5.42.5. Safety
Safety was evaluated in all patients treated with at least one dose of any study
medication, by parameters including reported adverse events (AEs), serious adverse
events (SAEs), vital signs, and clinical laboratory and electrocardiographic assess-
ments. AE incidence was assessed for each study period (i.e., dose conversion, each
double-blind treatment, and washout), with each AE assigned to the period inwhich
it started.Duration of levodopa treatment, years,
mean ± SD
6.8 (5.0) 7.0 (5.0)
Duration of entacapone treatment, years,
mean ± SD
2.8 (2.4) 2.9 (2.4)
Hoehn and Yahr score, mean ± SD 2.4 ± 0.7 2.4 ± 0.7
Total UPDRS score in “on” state, mean ± SD 41.4 ± 16.9 41.8 ± 17.1
Daily frequency of CD-LD IR, mean ± SD 5.0 ± 1.2 5.0 ± 1.2
Daily dose of CD-LD IR, mg, mean ± SD 660.4 ± 246.8 652.4 ± 251.9
Daily frequency of entacapone, mean ± SD 4.7 ± 0.8 4.7 ± 0.9
Daily dose of entacapone, mg, mean ± SD 940.7 ± 170.0 942.9 ± 174.4
“Off” time, % of waking day, mean ± SD 36.3 ± 16.1 36.1 ± 16.3a
“Off” time, hours/day, mean ± SD 5.9 ± 2.6 5.9 ± 2.7a
“On” time without troublesome dyskinesia,
hours/day, mean ± SD
9.9 ± 2.9 9.8 ± 3.0a
“On” time without dyskinesia, hours/day,
mean ± SD
7.8 ± 3.6 7.8 ± 3.6a
“On” time with non-troublesome dyskinesia,
hours/day, mean ± SD
2.1 ± 2.8 2.1 ± 2.7a
“On” time with troublesome dyskinesia,
hours/day, mean ± SD
0.6 ± 1.1 0.6 ± 1.2a
CD-LD IR, immediate-release carbidopaelevodopa; SD, standard deviation; PD,
Parkinson's disease.
a n ¼ 83.2.6. Statistical analyses
Sample-size determination is described in Supplementary Materials. Efﬁcacy
analyses included patients with at least 2 days of evaluable diary data from both
double-blind treatment periods. For post-hoc sensitivity analyses, the worst avail-
able observations from patients who discontinued early were used for IPX066
treatment, and the best available observations for CL þ E treatment; missing pref-
erences for treatment were assigned to CLþ E, and drop-outs were classiﬁed as non-
responders to their uncompleted treatment.
All endpoints except patient preference for treatment and proportion of patients
achieving thresholds of “off” time improvement were analyzed using a standard
mixed-effect model with variance at a 0.05 signiﬁcance level, treatment, sequence,
and period as ﬁxed effects, and inter- and intra-subject factors as random effects.
Patient preference for treatment was analyzed by chi-square test. To control for
type-1 error, key secondary endpoints were evaluated in a pre-speciﬁed hierarchical
order (“off” time; “on” time without troublesome dyskinesia; UPDRS II þ III score;
patient preference for treatment) only if the primary measure showed signiﬁcance
between treatments. Measures analyzed without controlling for multiple compar-
isons included “on” time with troublesome dyskinesia, diary-based responder data,
and scores on individual UPDRS parts, UPDRS Part II in the “off” state, EQ-5D, SF-36,
and PDSS. Statistical analyses were performed using SAS version 9.1 (SAS Institute
Inc., Cary NC).3. Results
Of 110 patients who entered the dose-conversion period, 91
were randomized, and 84 completed both crossover periods
(Fig. 1B). Because one patient did not have diary data for the second
double-blind period, 83 patients were analyzed for diary-related
endpoints.
Baseline demographic and clinical characteristics of completers
and of all randomized patients were similar (Table 1).3.1. Dosing
Among the 84 completers, the median (mean ± SD) daily LD
dosage during double-blind treatment was 1495 mg (1723 ± 713)
for IPX066 and 600 mg (652 ± 252) for CL þ E. For entacapone, the
median (mean ± SD) daily dosage was 800 mg (943 ± 174). The
median (mean ± SD) daily number of doses was 3.0 (3.5 ± 0.6) for
IPX066, 5.0 (5.0 ± 1.2) for CD-LD IR, and 4.0 (4.7 ± 0.9) for
entacapone.3.2. Efﬁcacy
On the primary endpoint (Fig. 2A), patients had a signiﬁcantly
lower mean percent “off” time during waking hours on IPX066
treatment than on CL þ E treatment, at 24.0% ± 16.2% vs.
32.5% ± 21.9% (p < 0.0001), corresponding to a decrease from
baseline of 34% vs. 10%. At baseline, patients had an average of 36.1%
“off” time during waking hours; at the end of dose conversion, the
average was 22.8%, a percentage similar to that observed during
IPX066 treatment under blinded conditions. No treatment-period
effect was observed (p ¼ 0.6997).
Fig. 2. Primary and key secondary efﬁcacy endpoints among patients who completed
the study and had complete PD Diary data (n ¼ 83). A) Primary endpoint of mean
percent “off” time during waking hours. B) Mean “off” time during waking hours per
day. C) Mean “on” time without troublesome dyskinesia during waking hours per day.
Table 2
Adverse events 2% in any treatment.
AE preferred term Dose
conversion
Randomized
crossover treatment
Open-label
washout
IPX066
(n ¼ 110)
IPX066
(n ¼ 89)
CL þ E
(n ¼ 88)
IPX066
(n ¼ 89)
Any AE, n (%) 34 (30.9) 18 (20.2) 12 (13.6) 12 (13.5)
Serious AEs, n (%) 2 (1.8) 1 (1.1) 0 1 (1.1)
AE leading to withdrawal 1 (0.9) 0 0 1 (1.1)
Common AEs, n (%)
Nausea 8 (7.3) 1 (1.1) 0 0
Fall 3 (2.7) 1 (1.1) 2 (2.3) 0
Upper respiratory tract
infection
3 (2.7) 0 0 0
Vomiting 3 (2.7) 1 (1.1) 0 0
Dyskinesia 1 (0.9) 4 (4.5) 0 1 (1.1)
Insomnia 1 (0.9) 3 (3.4) 0 0
Confusional state 0 3 (3.4) 0 0
AE, adverse event; CL þ E, CD-LD plus entacapone.
F. Stocchi et al. / Parkinsonism and Related Disorders 20 (2014) 1335e13401338Key secondary endpoints also signiﬁcantly favored IPX066
(Fig. 2B and C). At end of study, the mean “off” time had decreased
to 3.8 h/day during IPX066 and to 5.2 h/day during CL þ E treat-
ment, from 5.9 h/day at baseline, and the mean “on” time without
troublesome dyskinesia had increased to 11.4 h/day during IPX066
and to 10.0 h/day during CL þ E treatment, from 9.8 h/day atbaseline. Hence, compared with CL þ E treatment, IPX066 resulted
in 1.4 h less daily “off” time and 1.4 h more daily “on” time without
troublesome dyskinesia (both p < 0.0001). At endpoint, the treat-
ments exhibited no signiﬁcant difference in mean daily “on” time
with non-troublesome dyskinesia (2.7 ± 3.3 h for IPX066 vs.
2.3 ± 3.3 h for CL þ E; p ¼ 0.187) or “on” time with troublesome
dyskinesia (0.9 ± 1.9 h vs. 0.7 ± 1.6 h; p ¼ 0.3051). At study end,
UPDRS II þ III scores in the “on” state averaged 29.3 ± 15.0 for
IPX066 and 31.7 ± 14.9 for CL þ E (p ¼ 0.0233). Differences in
treatment preference were statistically signiﬁcant (p ¼ 0.0008),
with a higher proportion of completers preferring IPX066 (52.4%)
relative to CL þ E (27.4%) or no preference (20.2%).
In the study's post-hoc sensitivity analyses, which conserva-
tively imputed data for 7 discontinued patients, mean percent “off”
time during waking hours remained signiﬁcantly lower for IPX066
than for CL þ E (25.2% vs. 32.2%; p ¼ 0.0003). Similarly, results
signiﬁcantly favored IPX066 on the four key secondary endpoints of
mean “off” time (p ¼ 0.0005), “on” time without troublesome
dyskinesia (p ¼ 0.0002), UPDRS II þ III score (p ¼ 0.0437), and
treatment preference (p ¼ 0.0025).
In responder analyses, the proportion of completers achieving
each threshold of “off” time reduction was signiﬁcantly higher for
IPX066 than for CL þ E (Supplementary Fig. 1). When all random-
ized patients were included (with drop-outs classiﬁed as non-
responders), the proportions of patient achieving each threshold
remained numerically higher for IPX066 (data not shown), with
statistical signiﬁcance for thresholds of 1, 1.5, and 3 h.
Among EQ-5D domains, only Anxiety/Depression showed a
signiﬁcantly higher proportion of patients reporting no problems
during IPX066 than during CL þ E treatment (61.9% vs. 52.4%;
p ¼ 0.0443). For the other domains and the visual-analog-scale
assessment of current health status, results were directionally
better for IPX066 but did not reach statistical signiﬁcance. The SF-
36 Physical Component Summary score signiﬁcantly favored
IPX066 over CL þ E (40.8 ± 10.2 vs. 39.5 ± 9.9; p ¼ 0.0296), but
Mental Component Summary scores were similar (46.1 ± 10.7 vs.
45.6 ± 9.2; p ¼ 0.5330). Total PDSS scores were also similar
(103.5 ± 25.1 vs. 104.1 ± 24.5; p ¼ 0.7920).
3.3. Safety
During IPX066 dose conversion, 30.9% of patients reported AEs
(Table 2), with nausea (7.3%), vomiting (2.7%), fall (2.7%), and upper
respiratory tract infections (2.7%) the most common AE types.
During double-blind treatment, 20.2% of patients reported AEs
on IPX066 and 13.6% did so on CL þ E. The types reported by  2
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confusional state (n ¼ 3; 3.4%) on IPX066, and fall (n ¼ 2; 2.3%) on
CL þ E. During open-label IPX066 washout, 13.5% of patients re-
ported AEs. No AE type occurred in more than one patient.
Four patients reported SAEs, two during IPX066 dose conversion
(hypercalcemia in one patient; atrial ﬁbrillation, constipation, and
chemical gastroenteritis in the other), one during double-blind
IPX066 treatment (sciatica), and one during IPX066 washout
(dehydration). None of the SAEs was considered treatment-related.
Two patients discontinued due to AEs, one during IPX066 dose
conversion (dyspepsia, nausea, and vomiting) and one during
open-label IPX066 treatment between the double-blind treatment
periods (dyskinesia). No deaths occurred.
4. Discussion
At an approximately 22% higher LD exposure, but also a reduced
dosing frequency, IPX066 signiﬁcantly decreased percent “off” time
during waking hours, by 34% during IPX066 treatment compared
with 10% during CL þ E treatment. A correspondingly greater
decrease in “off” time (1.4 h) and a greater increase in “on” time
without troublesome dyskinesia (1.4 h) were also observed. The
effects of IPX066 on thesemeasures during the double-blind period
were similar to those observed after patients completed the open-
label dose-conversion period. The effects are robust, as demon-
strated by a post-hoc sensitivity analysis employing conservative
imputation methods. The effects are also consistent with the 1.2 h
greater reduction in “off” time observed in a 13-week randomized,
double-blind comparison of IPX066 and CD-LD IR in advanced,
ﬂuctuating PD [21].
The plasma proﬁle of IPX066 in patients with advanced PD ex-
hibits a rapid onset and prolonged duration of LD absorption, as
well as reduced LD peak/trough ﬂuctuation [14,22]. Because this
proﬁle differs from those of other LD products, the present study
included a 6-week dose-conversion period to allow time for dose
adjustment. For the initial conversion from CLE or CLþ E to IPX066,
the dose-conversion table provided in the study protocol was based
on the patient's total daily LD dosage in CLE or CLþ E at study entry.
As entacapone is known to increase LD bioavailability by approxi-
mately 35%e40% [23], the initial IPX066 doses provided by the
table were approximately 30% higher than had been provided for
converting CD-LD IR to IPX066 [21].
Among study completers, the daily LD dosage in patients'
IPX066 was approximately 2.6 times the LD dosage in their CL þ E
regimens. With adjustment for a 47% bioavailability compared with
the LD in CL þ E (from a subset of study patients [24]), it can be
estimated that the LD exposure provided by IPX066 was approxi-
mately 22% higher than that provided by CL þ E. Nevertheless, “on”
time with troublesome dyskinesia showed no signiﬁcant difference
between the two treatments.
Overall, IPX066 demonstrated acceptable tolerability. Although
the incidence of AEs during double-blind treatment was higher on
IPX066 (20.2%) than on CLþ E (13.6%), the AEs were consistent with
those reported in comparable studies of CD-LD or CL þ E therapies
[8,9,25,26], and were mainly neuropsychiatric or gastrointestinal.
None of the SAEs was considered treatment-related.
A potential limitation of the present study is that it did not
permit adjustment of CL þ E regimens but allowed 6 weeks of dose
conversion from CLþ E to IPX066. Given the amount of “off” time at
baseline, it is possible that increased LD exposure was necessary. If
adjustment of the CL þ E regimen had been permitted, the differ-
ences in treatment outcomes might have been smaller than were
observed [27]. However, it can also be hypothesized that the
patients might have undergone only minimal CL þ E adjustment
given that all were on a stable regimen of CLE or CL þ E for4weeks at study entry. In a recent study comparing IPX066 to CD-
LD IR in advanced PD patients who had been on a stable dose of CD-
LD IR [21], a 3-week dose adjustment period for CD-LD IR resulted
in an average increase of 31.1 mg/day of levodopa. Only 30.8% of
patients increased their total daily dose, 60.4% had no change, and
8.8% decreased their daily dose of levodopa. The dose adjustment
period resulted in a 0.42 h mean improvement in “off” time. If
similar changes were seenwith CLþ E doses in the current study, it
is unlikely that these changes would have resulted in a treatment
effect matching that produced by IPX066. Additionally, entacapone
is usually used to treat patients whose PD is inadequately
controlled by CD-LD IR alone, and these patients had already been
treated with CLE or CL þ E for a mean 2.9 ± 2.4 years at enrollment.
Another potential limitation is that the double-blind treatment
periods were only 2weeks per treatment, whichmay be considered
too short to identify true treatment differences. However, in the
study comparing IPX066 and CD-LD IR in advanced PD referenced
above [21], the motor effects observed 3 weeks after randomization
were maintained for both treatments throughout the trial's 13-
week double-blind treatment period. This is consistent with the
general observation that in advanced PD, LD effects are mostly
acute [28]. For these reasons, the design of the present study may
be considered adequate to provide guidance on differences in ef-
ﬁcacy and safety between IPX066 and CL þ E in this patient
population.
Despite these limitations, the consistency of the study's results
across endpoints suggests that IPX066 treatment may improve the
motor effects of LD and provide acceptable tolerability in PD pa-
tients inadequately treated with CLE or CL þ E. The observed dif-
ferences between the study's double-blind treatments appear to
have been clinically meaningful to such patients, as a signiﬁcantly
greater proportion of patients preferred IPX066 to CL þ E. The
plasma proﬁle of IPX066 may have contributed to the treatment's
efﬁcacy and safety. Larger and longer-term studies may be war-
ranted to conﬁrm the utility of IPX066 in advanced PD.
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